Newborn Jaundice Treatment Market Report 2026

The newborn jaundice treatment market size has grown strongly in recent years. It will grow from $2.71 billion in 2025 to $2.84 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to high prevalence of neonatal jaundice cases globally, limited availability of advanced phototherapy devices in low-resource settings, reliance on conventional fluorescent lamp-based treatment systems, delayed diagnosis of hyperbilirubinemia in newborns, lack of standardized neonatal screening protocols.

The newborn jaundice treatment market size is expected to see strong growth in the next few years. It will grow to $3.49 billion by 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising adoption of LED-based phototherapy systems, increasing focus on early neonatal screening programs, growing demand for home-based newborn care solutions, advancements in non-invasive bilirubin monitoring technologies, expansion of neonatal intensive care infrastructure globally. Major trends in the forecast period include LED-based intensive phototherapy systems for rapid bilirubin reduction in neonates, fiber-optic blanket phototherapy enabling continuous treatment with minimal infant disruption, smart bilirubin monitoring systems integrated with real-time phototherapy adjustment, portable homecare phototherapy devices supporting early hospital discharge, dual-surface phototherapy units enhancing treatment efficiency in neonatal intensive care.

The rising birth rates are expected to drive the growth of the newborn jaundice treatment market in the coming years. Birth rates refer to the number of live births within a specific population during a given period, reflecting overall population growth and reproductive patterns. The increase in birth rates is supported by improved access to maternal healthcare, population expansion, and favorable government policies in certain regions, resulting in a larger number of newborns requiring postnatal care. Newborn jaundice treatment contributes to this trend by supporting early diagnosis and effective management of bilirubin levels in the expanding neonatal population through phototherapy and related treatment methods, thereby lowering the risk of complications. For instance, in July 2025, according to the Office for National Statistics, a UK-based government department, there were 594,677 live births recorded in England and Wales in 2024, an increase of 3,605 births (0.6%) compared to 2023, marking the first increase since 2021. Therefore, rising birth rates are driving the growth of the newborn jaundice treatment market.

Leading companies operating in the newborn jaundice treatment market are focusing on advanced non-invasive screening solutions, such as smartphone-based bilirubin detection technologies, to support early diagnosis and improve accessibility to care. Smartphone-based bilirubin detection uses mobile imaging and algorithm-based analysis of skin coloration to estimate bilirubin levels without requiring blood sampling or specialized equipment. For instance, in July 2024, Konica Minolta, a Japan-based technology company, collaborated with Picterus AS, a Norway-based digital health company, to strengthen non-invasive jaundice screening solutions. The collaboration utilizes smartphone-based imaging to support early detection, improve accessibility in low-resource settings, and enable timely intervention while maintaining screening accuracy. In addition, the solution reduces dependence on hospital-based diagnostic equipment and facilitates point-of-care screening in community and homecare environments. It also supports scalable neonatal screening programs by providing cost-effective and user-friendly technology for healthcare professionals.

In February 2026, Natus Sensory, a US-based medical technology company, acquired TheraB Medical for an undisclosed amount. Through this acquisition, Natus Sensory expanded its neonatal care portfolio by integrating wearable phototherapy technology, strengthening innovation in bilirubin management solutions, and broadening treatment accessibility across hospital and alternative care environments. TheraB Medical is an Israel-based medical device company specializing in wearable phototherapy solutions for neonatal jaundice management.

Major companies operating in the newborn jaundice treatment market are Koninklijke Philips N. V., GE HealthCare Technologies, Drägerwerk AG & Co. KGaA, Heal Force Bio-Meditech Holdings Limited, Atom Medical, Ningbo David Medical Device, Fanem Ltd., MTTS Inc., Phoenix Medical Systems, Olidef Medical, Dixion Vertrieb Medizinischer Geräte GmbH, Anandic Medical Systems AG, Weyer GmbH, AVI Healthcare Pvt. Ltd., Nice Neotech, Natus Medical, Ibis Medical, Novos Medical Systems, GINEVRI Srl, Solarc Systems Inc., Cobams Srl, Kay & Company, Nareena Lifesciences Private Limited, Alfamedic, Delta.

North America was the largest region in the newborn jaundice treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the newborn jaundice treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the newborn jaundice treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The newborn jaundice treatment market consists of revenues earned by entities by providing services such as diagnostic testing services, phototherapy treatment services, neonatal monitoring services, bilirubin screening services, and neonatal nursing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The newborn jaundice treatment market also includes sales of phototherapy devices, bilirubin monitoring systems, fiber optic phototherapy blankets, and neonatal care equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.